Discover evidence-based strategies for healing diabetic wounds, from immediate care steps to advanced treatments, nutritional ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Slow wound healing and related complications are common in diabetes. Compromised blood circulation and nerve damage are among the causes of delayed recovery in people with diabetes. Foot ulcers ...

Diabetes is a multifaceted condition that can result in severe complications, including limb loss. Two major concerns are poor circulation and diminished sensation in the feet, which heighten the risk ...

Cell Analysis of Debrided Diabetic Foot Ulcers Reveals Dysregulated Wound Healing Environment in Non-Hispanic Black Patients,” published in the March 2025 issue of Journal of Investigative Dermatology ...

The US regulator has approved the first ever shock wave wound healing device, for use in patients with diabetic foot ulcers. The Dermapace System from Sanuwave is intended for use with chronic ...

To understand how A. faecalis influenced diabetic healing, the researchers did several types of tests with diabetic mice, ...

Skin wounds and sores, such as diabetic foot sores and pressure wounds, present a growing healthcare problem. These injuries are exacerbated by co-morbidities affecting circulation and healing ...

The global wound evacuators market is on a steady growth trajectory, with its size estimated at USD 383.3 million in 2022, and projected to reach USD 593.6 million by 2032, expanding at a CAGR of 4.1% ...

Diabetes is a long-term condition caused by defi­ciency in quantity or function of insulin, the chemical controlling the level of sugar in the blood. People with diabetes par­ticularly when ...

The process of wound healing is intricate and demands adequate nutrition to bolster the body’s inherent healing capability. Protein is crucial in this procedure, aiding in tissue recovery and ...

FibroBiologics, Inc. (NASDAQ:FBLG) is continuing preparations for a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product candidate, in patients suffering from diabetic foot ulcers (DFUs ...